FORT MYERS, Fla., February 3, 2020 — The American Oncology Network, LLC (AON) in-house specialty pharmacy has announced recent accreditation by URAC. The organization is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. By achieving this status, AON Pharmacy demonstrated a comprehensive commitment to quality care, improved processes and better patient outcomes. The AON specialty pharmacy, based in Fort Myers, Florida, works exclusively on behalf of more than 70 physicians in its growing network of community-based oncology practices to deliver oral cancer medications to their patients’ homes. Oral anti-cancer medication currently comprises 25% to 30% of the oncology treatments provided to patients nationwide.
“AON Pharmacy should be commended for meeting these rigorous national quality standards,” said AON CEO Brad Prechtl, MBA. “This accreditation represents our commitment to our physicians and their patients to providing the highest quality of services to ensure patient safety.”
For more about AON’s accreditation, see the full press release.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More